ALK Peptide Vaccination Restores the Immunogenicity of ALK-Rearranged Non-Small Cell Lung Cancer

Scientists identified immunogenic anaplastic lymphoma kinase (ALK) peptides to show that immune checkpoint inhibitors induced rejection of ALK+ tumors in the flank but not in the lung. A single-peptide vaccination restored priming of ALK-specific CD8+ T cells, eradicated lung tumors in combination with ALK TKIs, and prevented metastatic dissemination of tumors to the brain.